Navigation Links
United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
Date:7/28/2011

$

104,894$

96,3678.8%Tyvaso

61,80929,483109.6%Adcirca

16,8438,58996.1%Other

205282(27.3)%Total net revenues

$

183,751$

134,72136.4%Revenues for the quarter ended June 30, 2011 increased by $49.0 million, compared to the quarter ended June 30, 2010. The growth in revenues primarily reflects the increase in the number of patients being prescribed our products.

Expenses

The table below summarizes research and development expense by major project and non-project components (dollars in thousands):Three Months EndedJune 30,20112010Percentage ChangeProject and non-project component:Cardiopulmonary

$

24,490$

18,61931.5%Share-based compensation

(9,555)1,420(772.9)%Other

9,3058,5488.9%Total research and development expense

$

24,240$

28,587(15.2)%Cardiopulmonary. The increase in expenses related to our cardiopulmonary projects for the quarter ended June 30, 2011 was attributable largely to increases in expenses related to our FREEDOM-C2 and FREEDOM-M clinical trials and our development of beraprost-MR.

Share-based compensation. The decrease in share-based compensation for the quarter ended June 30, 2011, compared to the same quarter in 2010, corresponded to a reduction in share-based compensation recognized in connection with our share tracking awards plans as a result of the decrease in our stock price.

The table below summarizes selling, general and administrative expense by major categories (in thousands):Three Months EndedJune 30,20112010Percentage ChangeCategory:General and administrative

$

24,268$

18,75429.4%Sales and marketing

17,07212,90032.3%Share-based compensation

(17,484)(2,000)(774.2)%Total selling, general and administrative expense

$

23,856$

29,654(19.6)%General and administrative. The increase in general and administr
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States
2. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
3. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
4. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
5. United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
6. United Therapeutics Corporation to Announce Fourth Quarter and Annual 2010 Financial Results Before Market Open on Tuesday, February 15, 2011
7. United Therapeutics Corporation Reports Third Quarter 2010 Financial Results
8. United Therapeutics Corporation to Announce Third Quarter 2010 Financial Results Before Market Open on Thursday, October 28, 2010
9. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
10. United Therapeutics Corporation to Announce Second Quarter 2010 Financial Results Before Market Open on Wednesday, July 28, 2010
11. Report Details How States Respond to Citizens United Decision
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... SonaCare Medical, a leading manufacturer of ... participated in the American Urology Association’s (AUA) surgical ... opinion leaders in urology presented on the latest ... masses while attendees had the opportunity to evaluate ... labs. Attendees at the Los Angeles, CA lab, ...
(Date:11/26/2014)... 25, 2014 The Pittcon marketing department ... conference and exposition mobile app, Pittcon ... in the App Store for iOS and Android devices ... tool before, during and after the event. It acts ... exhibiting companies, technical sessions, Conferee Networking sessions and short ...
(Date:11/26/2014)... Boston, MA (PRWEB) November 26, 2014 ... and collaboration company is proud to announce that Darren ... Development and Sales. Darren will drive the ... and positive customer experience. , Darren brings ... He has held key roles in channel operations, from ...
(Date:11/26/2014)... 2014 Theravalues Corporation est fier d,annoncer ... européen au salon Hi Europe 2014 (du 2 ... Curcumine la plus biodisponible actuellement sur ... à des ingrédients approuvés par les règlements européens. ... présent dans la racine de curcuma ( Curcuma ...
Breaking Biology Technology:SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Pittcon Releases 2015 Mobile App 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3
... , , WARSAW, ... ZMH ; SWX: ZMH) today announced the launch of the new ... surgeons and subject matter experts to develop a unique model for ... Surgeon-to-Surgeon programs under one, consolidated service offering, the enhanced Zimmer Institute ...
... EL SEGUNDO, Calif., July 27 NASA has exercised a ... continuing support to the Space Life Sciences Directorate at NASA,s Johnson ... The work will be done by Wyle,s Integrated Science and ... the bioastronautics contract, Wyle,s work supports the International Space Station, space ...
... , SOUTH PLAINFIELD, N.J., July 27 ... Phase 2 clinical trial of PTC299 in adult patients with ... the development of non-malignant brain tumors. PTC299 is a ... selectively block tumor-related vascular endothelial growth factor (VEGF). With ...
Cached Biology Technology:Zimmer Launches New Medical Education and BioSkills Training Program 2Zimmer Launches New Medical Education and BioSkills Training Program 3Zimmer Launches New Medical Education and BioSkills Training Program 4NASA Extends Bioastronautics Contract With Wyle for Total Value of $976 Million 2PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 2PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 3PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 4
(Date:11/4/2014)... 2014 – University of Utah engineers developed the first ... fuel produce electricity without needing to ignite the fuel. ... portable electronics, off-grid power and sensors. , A study ... American Chemical Society journal ACS Catalysis . , ... reaction between a fuel and an oxygen-rich source such ...
(Date:11/4/2014)... newly published research study examining only marketing directed ... fast food restaurants has found that the majority ... exposed to such marketing tactics. , Authored by ... colleagues, the study is the first to examine ... and exterior of fast food restaurants and its ...
(Date:11/3/2014)... Research and Markets has announced the addition of a ... to their offering. This report describes ... started to play an important role in the practice of ... bone marrow transplants. Role of cells in drug discovery is ... of medical practice. Stem cells are discussed in ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... burn cleaner, a research report published in the January ... the food industry could take a similar approach toward ... additives would be based on work of Israeli researchers ... wine, fruits, and vegetables) simultaneously with high-fat foods may ...
... a higher prevalence of body abnormalities, such as asymmetric lower ... defect responsible for the abnormality may play a role in ... January 2 issue of JAMA. Certain genetic syndromes ... cancer development in children. Several studies have shown that developmental ...
... that doctors treating life-threatening emergencies such as allergy attacks may ... labelling. Adrenaline is stored in salt water in glass ... The amount of adrenaline contained in the ampoule is ... drug per 1 mL of salt water) and a ratio ...
Cached Biology News:Study examines genetic defects linked to body abnormalities in patients with childhood cancer 2Doctors may be giving the wrong dosage of adrenaline in an emergency because of labelling 2
Human PDGF, CF...
... utility and flexibility press-to-seal silicone isolators can ... the researcher. They are available either pre-cut ... material that can be easily trimmed to ... and non-cytotoxic and can be used to ...
... The mycobacteria in Complete Freund's ... the injection site which enhances the immuneresponse. ... is used for the initial injections; Incomplete ... boosts. Antigens (preferably in saline) are typically ...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
Biology Products: